The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development of a multiparametric prognostic score based on PAM50, in patients with HR+/HER2- advanced breast cancer (aBC) treated with endocrine therapy (ET) plus cyclin dependent kinase 4 and 6 inhibitors (CDKi), within the CDK-PREDICT (SOLTI-1801) study and HCB cohort.
 
Pablo Tolosa Ortega
Consulting or Advisory Role - Adamed; AstraZeneca; Daiichi Sankyo; Novartis; Seagen
Speakers' Bureau - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Seagen
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Pfizer
 
Tomás Pascual
Honoraria - Argenetics; AstraZeneca; Lilly; Novartis; Veracyte
Consulting or Advisory Role - Novartis; Roche/Genentech
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Veracyte
 
Olga Martínez-Sáez
No Relationships to Disclose
 
Cristina Hernando
No Relationships to Disclose
 
Sonia Servitja
No Relationships to Disclose
 
María Fernández-Abad
Honoraria - AstraZeneca Spain; DAIICHI SANKYO ESPANA SAU; Eisai; Lilly; Novartis
Consulting or Advisory Role - Lilly; Novartis
Travel, Accommodations, Expenses - Novartis
 
Fara Brasó-Maristany
Employment - Reveal Genomics
Patents, Royalties, Other Intellectual Property - DNADX patent filed; HER2DX patent filed
 
Esther Sanfeliu Torres
No Relationships to Disclose
 
Javier Benítez
No Relationships to Disclose
 
Laura Lema
No Relationships to Disclose
 
Yolanda Ruano
No Relationships to Disclose
 
Isabel García-Fructuoso
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Eisai; Esteve; Novartis
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis
 
Adela Rodríguez
No Relationships to Disclose
 
Lucia Parrilla
No Relationships to Disclose
 
María Ángeles Cobos-Fernández
No Relationships to Disclose
 
Guillermo Villacampa
Honoraria - Reveal Genomics
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
Speakers' Bureau - MSD Oncology; Pfizer; Pierre Fabre
 
Jordi Canes
No Relationships to Disclose
 
Fernando Salvador
No Relationships to Disclose
 
Aleix Prat
Employment - Reveal Genomics
Leadership - Reveal Genomics
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - AstraZeneca; Daiichi Sankyo; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Novartis; Oncolytics; Pfizer; Roche
Research Funding - AstraZeneca; Daiichi Sankyo; Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; TNBC-DX
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Eva Ciruelos
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Novartis; Pfizer; Roche; Seagen
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Roche
Research Funding - Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche